-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Receives Approval for Nicethamide API
Category:
发布时间：2025-01-02
【概要描述】
On December 30, nicethamide, developed by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed dosage forms. To date, the Group has a total of 67 API products.
On December 30, Nicethamide, developed by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed dosage forms. To date, the Group has a total of 67 API products.
According to available information, nicethamide API is primarily used for central respiratory depression and respiratory suppression caused by various etiologies; it is a class of central stimulants, and its injectable formulation is mainly indicated for the treatment of conditions such as respiratory or circulatory failure.
In the first batch of “Challenge-based Recruitment” projects for critical core technologies and products in the industrial sector, released by the Hebei Provincial Department of Industry and Information Technology in January of this year, Guangxiang Pharmaceutical Group successfully secured the contract to develop a production process for nicethamide API. This project primarily addresses the challenges of nicethamide’s high susceptibility to oxidation, stringent transportation and storage requirements, and difficulties in scaling up for industrial production, thereby laying the foundation for the industrialization of nicethamide API.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091